GET DAILY SIGNALSWhy Is U.S. Physical Therapy (USPH) Stock Up +8.98% Today?
Key Takeaways
- USPH shares climbed roughly +8.98% intraday, rising from a prior close of $89.18 to about $97.19.
- The primary catalyst was a stronger-than-expected third-quarter 2026 earnings report, with revenue and adjusted EPS both topping Wall Street consensus.
- Record patient visits and record revenue per visit, alongside accelerating hospital-affiliation revenue, reinforced the bullish narrative.
- Analysts raised the average 12-month price target to $99, with a consensus Buy rating across covering firms.
- The move outpaced the broader healthcare sector, reflecting stock-specific momentum rather than a market-wide rally.
- Traders are now watching margin trends, hospital-affiliation growth, and any post-earnings analyst estimate revisions.
- For additional context on valuation and technicals, explore Price Targets, Earnings, and Forecast pages.
- To see how AI-driven strategies are positioning across the market, visit Trending AI Robots.
Opening Summary
U.S. Physical Therapy, Inc. (USPH), a Houston-based operator of roughly 800 outpatient physical therapy clinics and an industrial injury prevention business, saw its shares surge on Wednesday. The stock climbed approximately +8.98% to around $97.19, up from a prior close of $89.18. The rally was driven primarily by a strong third-quarter earnings beat, with markets reacting positively to accelerating revenue growth, record patient visit volumes, and encouraging commentary around the company's hospital-affiliation strategy.
Earnings Results and Guidance
The centerpiece of the move was a third-quarter 2026 report that came in ahead of expectations. USPH posted revenue of approximately $222.6 million, up 12.9% year over year and above the roughly $214 million consensus estimate. Adjusted earnings per share of $0.80 beat the consensus of about $0.73, while adjusted EBITDA also exceeded projections. Management attributed the improvement to early benefits from the rollout of its hospital-affiliation agreements and described the quarter as a strong financial performance following a disappointing second quarter.
Record Patient Volumes and Hospital Affiliation Momentum
Beyond the headline numbers, investors focused on underlying operating strength. USPH reported a record 1.68 million patient visits and record revenue per visit, signaling healthy demand across its network. Revenue from its 72 hospital-affiliated clinics reached roughly $25 million during the quarter, and management indicated it expects this figure to grow as referral volumes rise, additional clinics are folded into existing agreements, and new hospital partnerships come online. This structural expansion story has become a key pillar of the company's growth thesis.
Analyst Reaction and Price Target Increase
The earnings beat was accompanied by a more constructive analyst stance. The average 12-month price target was raised to $99, implying further upside from current levels, with forecasts ranging from $95 to $102. The consensus rating remains a Buy, with six of seven covering analysts recommending purchase. This combination of a strong quarter and rising targets helped sustain the share-price rally throughout the session.
Market Context and Trading Activity
The move in USPH appeared largely company-specific, reflecting the earnings-driven repricing rather than a broad sector or index surge. Trading volume was elevated as investors repositioned following the report, and the stock's sharp gain suggested a technical breakout above its recent trading range. Medicare reimbursement rates increased by 3.3% for 2026 — a favorable industry backdrop — but the magnitude of today's move points most directly to the company's own results and guidance commentary.
What Comes Next for USPH
Looking ahead, investors will monitor whether USPH can sustain its margin recovery after the earlier second-quarter profit shortfall. Key items on the horizon include the pace of hospital-affiliation expansions, integration of recent acquisitions, and any post-earnings revisions to analyst estimates for the coming quarters. Risks include cost pressures, acquisition integration challenges, and potential fluctuations in reimbursement policy, all of which could temper momentum even after a strong report.
Trending AI Robots
Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing users to explore approaches suited to different market environments. If you're looking for data-driven ways to navigate shifting conditions, consider exploring the Trending AI Robots page today.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
USPH sees MACD Histogram just turned negative
USPH saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 28, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 42 instances where the indicator turned negative. In 32 of the 42 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 76%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for USPH moved out of overbought territory on October 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 22 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 58%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 42 of 59 cases where USPH's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where USPH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 66%.
USPH broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on USPH as a result. In 62 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
Following a +2.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where USPH advanced for three days, in 217 of 330 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
The Aroon Indicator entered an Uptrend today. In 152 of 254 cases where USPH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 60%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. USPH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 90 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.966) is normal, around the industry mean (204.059). USPH's P/E Ratio (524.588) is considerably higher than the industry average of (18.581). Projected Growth (PEG Ratio) (2.823) is also within normal values, averaging (2.498). Dividend Yield (0.021) settles around the average of (0.091) among similar stocks. P/S Ratio (1.556) is also within normal values, averaging (2.688).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. USPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer outpatient physical and occupational therapy clinics
Industry HospitalNursingManagement
Advertisement